Evidence mapPaperPMID 41716334Full record

ReviewMaterials today. Bio2026

Nanomedicine-based lactate metabolism and lactylation regulation for exploring new therapeutic strategies in cancer.

Shuzhe Cai, Siqi Li, Jingjing Liu

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuzhe CaiSchool of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou, 225009, China.
Siqi LiSchool of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou, 225009, China.
Jingjing LiuSchool of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou, 225009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactate, a key metabolite of glycolysis in tumor cells, plays a dual role in cancer progression. On one hand, it contributes to the formation of an acidic tumor microenvironment that fosters tumorigenesis and malignancy. On the other, it promotes tumor progression through protein lactylation, a recently identified post-translational modification. Consequently, targeting lactate metabolism and lactylation represents a critical therapeutic method in oncology. Advances in nanomedicine have opened new possibilities for precise modulation of lactate metabolism. Nanomedicine-based strategies enable the regulation of lactate production, transport, and clearance, thereby offering effective tools for tumor suppression. Additionally, the lactate induced lactylation orchestrated by lactyl-CoA, lactyltransferases, and delactylases offer more refined targets for investigating approaches to inhibit tumor progression. In this review, we comprehensively summarize recent developments in nanomedicine-based strategies for lactate metabolism modulation and the mechanism of lactylation regulation. We suppose the design of multifunctional nanoplatforms capable of simultaneously regulating lactate levels and lactylation could integrate metabolic and epigenetic interventions to disrupt lactate-driven tumor support mechanisms precisely and effectively for advancing cancer treatment paradigms.

Indexed as

Catalytic therapyFunctional nanomaterialsLactate metabolismProtein lactylationTumor microenvironment modulation

Identifiers

PMID41716334
PMCPMC12914674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.